NEJM Group

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

Posts Tagged ‘Transendocardial Mesenchymal Stem Cells’

RSS

January 6th, 2014

Selections from Richard Lehman’s Literature Review: January 6th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the NAVIGATOR study, trials of stents, mitral valve repair vs. replacement, and more.

Categories: General
Tags: atherosclerotic renal-artery stenosis, beta-blockers, cardiac arrest, cardiopulmonary resuscitation, COPD, defibrillation, diabetes, diuretics, hypothermia, impaired glucose tolerance, Ischemic cardiomyopathy, left ventricular assist device thrombosis, mechanical chest compressions, medical therapy, mitral repair, mitral replacement, Mononuclear Bone Marrow Cells, severe ischemic mitral regurgitation, stents, Transendocardial Mesenchymal Stem Cells


  • Search the Archive

  • Archives by Date

  • RSS NEJM — Recent Cardiology Articles

    • Descending Thoracic Aortic Aneurysm July 16, 2026
      A man presented with a 2-month history of chest heaviness and a 2-week history of shortness of breath. Pulsations were visible between his ribs (shown in a video). Ultrasonography revealed a rounded structure near the heart.
    • Balancing the Scales — Extended DAPT in Coronary Artery Disease July 16, 2026
      The appropriate duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has remained the subject of a central debate in cardiovascular medicine. DAPT is intended to mitigate ischemic risk, but its maintenance warrants balancing the benefit against the concomitant risk of hemorrhage.1 Consequently, determining the appropriate...
    • Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease July 16, 2026
      Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding.
    • Platelet-Activating Anti–Platelet Factor 4 Disorders July 13, 2026
      This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies.
    • Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty July 12, 2026
      After total hip or knee arthroplasty, aspirin alone was noninferior to rivaroxaban followed by aspirin in preventing symptomatic venous thromboembolism, with a similarly low risk of bleeding complications.
  • Tag Cloud

    • ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
NEJM Group

Copyright © 2026 Massachusetts Medical Society. All rights reserved.

The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy |